IL17A and psoriasis: The selection of which agent is at the clinician's discretion based upon comorbidities (eg the presence of inflammatory bowel disease would be a relative contraindication to IL‐17 inhibition,87 and the presence of psoriasis or axial spondyloarthropathy may be an indication for the use of IL‐17 inhibitors88).